Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium, Inc. (Nasdaq: EQ) presented a poster at the annual meeting of The American Association of Immunologists showcasing the role of CD6 in cell adhesion and migration, highlighting the efficacy of itolizumab in preventing trans-endothelial migration of effector T cells. The data revealed the mechanism of action of itolizumab and its ability to modulate T cell activity and trafficking, offering insights into treating autoimmune and inflammatory disorders.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
